Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B.

Abstract

BACKGROUND:

TNF-alpha promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus.

AIMS:

We investigated whether polymorphisms of TNF-alpha promoter at position -308 or -238 had associations with the response to lamivudine treatment.

METHODS:

A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-alpha promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group.

RESULTS:

The numbers of A allelic polymorphism of TNF-alpha promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015).

CONCLUSIONS:

Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-alpha promoter at position -238.

• Authors: Yong Kwang Park, Jung Min Lee, Do Young Kim, Hye Young Chang, Ja Kyung Kim, Chun Kyon Lee, Jun Yong Park, Sang Hoon Ahn, Kwan Sik Lee, Kwang Hyub Han
• Journal: Digestive diseases and sciences (Dig Dis Sci) Vol. 55 Issue 7 Pg. 2043-8 (Jul 2010) ISSN: 1573-2568 [Electronic] United States
• PMID: 19830555 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Tumor Necrosis Factor-alpha
• Lamivudine

Topics

• Adult
• Analysis of Variance
• Case-Control Studies
• Confidence Intervals
• Disease Progression
• Female
• Follow-Up Studies
• Gene Expression Regulation
• Genotype
• Hepatitis B, Chronic (diagnosis, drug therapy, genetics)
• Humans
• Lamivudine (therapeutic use)
• Liver Function Tests
• Male
• Middle Aged
• Multivariate Analysis
• Odds Ratio
• Polymorphism, Genetic
• Probability
• Promoter Regions, Genetic (drug effects)
• Reference Values
• Risk Assessment
• Severity of Illness Index
• Treatment Failure
• Treatment Outcome
• Tumor Necrosis Factor-alpha (genetics, metabolism)
• Young Adult